Cell & Gene: NK Cell Therapies – How Artiva Biotherapeutics Leverages Its “Manufacturing First” Approach

Chris Horan, chief technical operations officer, Artiva Biotherapeutics discusses with Cell & Gene natural killer (NK) cell therapies and Artiva’s experiences and strategies with its candidate, AlloNK.

He answers the following questions:

• Why do NK cell therapies hold promise in treating autoimmune disease?
• What is the biggest technical/scientific challenge of developing NK-based therapies, and what has been Artiva’s experience addressing that challenge?
• What are the best practices, or pitfalls to avoid, of cryopreservation?
• How is Artiva approaching clinical trials of its NK cell-based candidate, since patients need multiple doses?
• Can you tell us more about Artiva’s “manufacturing-first approach” and how it’s different from the traditional approach? How is Artiva approaching the closed process to minimize any variability?

Read the Q&A here.